EGFR and adenocarcinoma: The percentage of patients with a high CYFRA21‐1:CEA ratio was also significantly higher in the ALK group (28%) compared with the EGFR group (14%) in cases restricted to adenocarcinoma (p = 0.004) (Figure 3).